Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants

Elizabeth B. Lamont, James E. Herndon, Jane C. Weeks, I. Craig Henderson, Rogerio Lilenbaum, Richard L. Schilsky, Nicholas A. Christakis, Lee Schwartzberg, Stephen George, Stephen Grubbs, Jeffrey Kirshner, George P. Cannelos, Marc S. Ernstoff, Jeffrey Crawford, Robert L. Comis, Edward Gelmann, H. Herbert Mauer, John W. Kugler, Placido P. Ferreira, Jonathan A. PolikoffMark Citron, Michael L. Grossbard, Mark Green, Alan P. Lyss, Rogerio Lilenbaum, Lewis Silverman, Michael J. O'Connell, Daniel R. Budman, William Sikov, Ellis Levine, Jack Goldberg, James N. Atkins, John Ellerton, Charles Coltman, Arnold D. Rubin, Stephen L. Graziano, Jeffrey Kirshner, Clara D. Bloomfield, Robert Diasio, Stephen L. Seagren, Alan P. Venook, Gini Fleming, Lawrence Feldman, Gerald H. Clamon, Martin Edelman, F. Mary Ellen Taplin, Bruce A. Peterson, Michael C. Perry, Anne Kessinger, Thomas C. Shea, Harvey B. Niell, Lynn M. Steinbrenner, Hyman B. Muss, John D. Roberts, David D. Hurd, Joseph J. Drabeek, Nancy Bartlett, Scott Wadler

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93% (95% confidence interval [CI] = 88% to 96%). Individual chemotherapy agents had similarly high sensitivities, ranging from 81% (95% CI = 70% to 89%) for carboplatin to 91% (95% CI = 79% to 98%) for cyclophosphamide. Agent-specific specificities were 100%. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.

Original languageEnglish (US)
Pages (from-to)1080-1083
Number of pages4
JournalJournal of the National Cancer Institute
Volume97
Issue number14
DOIs
StatePublished - Jul 20 2005

Fingerprint

Medicare
Lung Neoplasms
Leukemia
Breast Neoplasms
Drug Therapy
Paclitaxel
Centers for Medicare and Medicaid Services (U.S.)
Neoplasms
Carboplatin
Confidence Intervals
Cyclophosphamide
Validation Studies
Health Insurance
Gold
Doxorubicin
Breast
Clinical Trials
Lung

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Lamont, E. B., Herndon, J. E., Weeks, J. C., Henderson, I. C., Lilenbaum, R., Schilsky, R. L., ... Wadler, S. (2005). Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants. Journal of the National Cancer Institute, 97(14), 1080-1083. https://doi.org/10.1093/jnci/dji189

Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants. / Lamont, Elizabeth B.; Herndon, James E.; Weeks, Jane C.; Henderson, I. Craig; Lilenbaum, Rogerio; Schilsky, Richard L.; Christakis, Nicholas A.; Schwartzberg, Lee; George, Stephen; Grubbs, Stephen; Kirshner, Jeffrey; Cannelos, George P.; Ernstoff, Marc S.; Crawford, Jeffrey; Comis, Robert L.; Gelmann, Edward; Mauer, H. Herbert; Kugler, John W.; Ferreira, Placido P.; Polikoff, Jonathan A.; Citron, Mark; Grossbard, Michael L.; Green, Mark; Lyss, Alan P.; Lilenbaum, Rogerio; Silverman, Lewis; O'Connell, Michael J.; Budman, Daniel R.; Sikov, William; Levine, Ellis; Goldberg, Jack; Atkins, James N.; Ellerton, John; Coltman, Charles; Rubin, Arnold D.; Graziano, Stephen L.; Kirshner, Jeffrey; Bloomfield, Clara D.; Diasio, Robert; Seagren, Stephen L.; Venook, Alan P.; Fleming, Gini; Feldman, Lawrence; Clamon, Gerald H.; Edelman, Martin; Taplin, F. Mary Ellen; Peterson, Bruce A.; Perry, Michael C.; Kessinger, Anne; Shea, Thomas C.; Niell, Harvey B.; Steinbrenner, Lynn M.; Muss, Hyman B.; Roberts, John D.; Hurd, David D.; Drabeek, Joseph J.; Bartlett, Nancy; Wadler, Scott.

In: Journal of the National Cancer Institute, Vol. 97, No. 14, 20.07.2005, p. 1080-1083.

Research output: Contribution to journalArticle

Lamont, EB, Herndon, JE, Weeks, JC, Henderson, IC, Lilenbaum, R, Schilsky, RL, Christakis, NA, Schwartzberg, L, George, S, Grubbs, S, Kirshner, J, Cannelos, GP, Ernstoff, MS, Crawford, J, Comis, RL, Gelmann, E, Mauer, HH, Kugler, JW, Ferreira, PP, Polikoff, JA, Citron, M, Grossbard, ML, Green, M, Lyss, AP, Lilenbaum, R, Silverman, L, O'Connell, MJ, Budman, DR, Sikov, W, Levine, E, Goldberg, J, Atkins, JN, Ellerton, J, Coltman, C, Rubin, AD, Graziano, SL, Kirshner, J, Bloomfield, CD, Diasio, R, Seagren, SL, Venook, AP, Fleming, G, Feldman, L, Clamon, GH, Edelman, M, Taplin, FME, Peterson, BA, Perry, MC, Kessinger, A, Shea, TC, Niell, HB, Steinbrenner, LM, Muss, HB, Roberts, JD, Hurd, DD, Drabeek, JJ, Bartlett, N & Wadler, S 2005, 'Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants', Journal of the National Cancer Institute, vol. 97, no. 14, pp. 1080-1083. https://doi.org/10.1093/jnci/dji189
Lamont, Elizabeth B. ; Herndon, James E. ; Weeks, Jane C. ; Henderson, I. Craig ; Lilenbaum, Rogerio ; Schilsky, Richard L. ; Christakis, Nicholas A. ; Schwartzberg, Lee ; George, Stephen ; Grubbs, Stephen ; Kirshner, Jeffrey ; Cannelos, George P. ; Ernstoff, Marc S. ; Crawford, Jeffrey ; Comis, Robert L. ; Gelmann, Edward ; Mauer, H. Herbert ; Kugler, John W. ; Ferreira, Placido P. ; Polikoff, Jonathan A. ; Citron, Mark ; Grossbard, Michael L. ; Green, Mark ; Lyss, Alan P. ; Lilenbaum, Rogerio ; Silverman, Lewis ; O'Connell, Michael J. ; Budman, Daniel R. ; Sikov, William ; Levine, Ellis ; Goldberg, Jack ; Atkins, James N. ; Ellerton, John ; Coltman, Charles ; Rubin, Arnold D. ; Graziano, Stephen L. ; Kirshner, Jeffrey ; Bloomfield, Clara D. ; Diasio, Robert ; Seagren, Stephen L. ; Venook, Alan P. ; Fleming, Gini ; Feldman, Lawrence ; Clamon, Gerald H. ; Edelman, Martin ; Taplin, F. Mary Ellen ; Peterson, Bruce A. ; Perry, Michael C. ; Kessinger, Anne ; Shea, Thomas C. ; Niell, Harvey B. ; Steinbrenner, Lynn M. ; Muss, Hyman B. ; Roberts, John D. ; Hurd, David D. ; Drabeek, Joseph J. ; Bartlett, Nancy ; Wadler, Scott. / Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants. In: Journal of the National Cancer Institute. 2005 ; Vol. 97, No. 14. pp. 1080-1083.
@article{338ffd9764b04550a20bf4481c9f11cc,
title = "Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants",
abstract = "To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93{\%} (95{\%} confidence interval [CI] = 88{\%} to 96{\%}). Individual chemotherapy agents had similarly high sensitivities, ranging from 81{\%} (95{\%} CI = 70{\%} to 89{\%}) for carboplatin to 91{\%} (95{\%} CI = 79{\%} to 98{\%}) for cyclophosphamide. Agent-specific specificities were 100{\%}. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.",
author = "Lamont, {Elizabeth B.} and Herndon, {James E.} and Weeks, {Jane C.} and Henderson, {I. Craig} and Rogerio Lilenbaum and Schilsky, {Richard L.} and Christakis, {Nicholas A.} and Lee Schwartzberg and Stephen George and Stephen Grubbs and Jeffrey Kirshner and Cannelos, {George P.} and Ernstoff, {Marc S.} and Jeffrey Crawford and Comis, {Robert L.} and Edward Gelmann and Mauer, {H. Herbert} and Kugler, {John W.} and Ferreira, {Placido P.} and Polikoff, {Jonathan A.} and Mark Citron and Grossbard, {Michael L.} and Mark Green and Lyss, {Alan P.} and Rogerio Lilenbaum and Lewis Silverman and O'Connell, {Michael J.} and Budman, {Daniel R.} and William Sikov and Ellis Levine and Jack Goldberg and Atkins, {James N.} and John Ellerton and Charles Coltman and Rubin, {Arnold D.} and Graziano, {Stephen L.} and Jeffrey Kirshner and Bloomfield, {Clara D.} and Robert Diasio and Seagren, {Stephen L.} and Venook, {Alan P.} and Gini Fleming and Lawrence Feldman and Clamon, {Gerald H.} and Martin Edelman and Taplin, {F. Mary Ellen} and Peterson, {Bruce A.} and Perry, {Michael C.} and Anne Kessinger and Shea, {Thomas C.} and Niell, {Harvey B.} and Steinbrenner, {Lynn M.} and Muss, {Hyman B.} and Roberts, {John D.} and Hurd, {David D.} and Drabeek, {Joseph J.} and Nancy Bartlett and Scott Wadler",
year = "2005",
month = "7",
day = "20",
doi = "10.1093/jnci/dji189",
language = "English (US)",
volume = "97",
pages = "1080--1083",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "14",

}

TY - JOUR

T1 - Criterion validity of medicare chemotherapy claims in cancer and leukemia group B breast and lung cancer trial participants

AU - Lamont, Elizabeth B.

AU - Herndon, James E.

AU - Weeks, Jane C.

AU - Henderson, I. Craig

AU - Lilenbaum, Rogerio

AU - Schilsky, Richard L.

AU - Christakis, Nicholas A.

AU - Schwartzberg, Lee

AU - George, Stephen

AU - Grubbs, Stephen

AU - Kirshner, Jeffrey

AU - Cannelos, George P.

AU - Ernstoff, Marc S.

AU - Crawford, Jeffrey

AU - Comis, Robert L.

AU - Gelmann, Edward

AU - Mauer, H. Herbert

AU - Kugler, John W.

AU - Ferreira, Placido P.

AU - Polikoff, Jonathan A.

AU - Citron, Mark

AU - Grossbard, Michael L.

AU - Green, Mark

AU - Lyss, Alan P.

AU - Lilenbaum, Rogerio

AU - Silverman, Lewis

AU - O'Connell, Michael J.

AU - Budman, Daniel R.

AU - Sikov, William

AU - Levine, Ellis

AU - Goldberg, Jack

AU - Atkins, James N.

AU - Ellerton, John

AU - Coltman, Charles

AU - Rubin, Arnold D.

AU - Graziano, Stephen L.

AU - Kirshner, Jeffrey

AU - Bloomfield, Clara D.

AU - Diasio, Robert

AU - Seagren, Stephen L.

AU - Venook, Alan P.

AU - Fleming, Gini

AU - Feldman, Lawrence

AU - Clamon, Gerald H.

AU - Edelman, Martin

AU - Taplin, F. Mary Ellen

AU - Peterson, Bruce A.

AU - Perry, Michael C.

AU - Kessinger, Anne

AU - Shea, Thomas C.

AU - Niell, Harvey B.

AU - Steinbrenner, Lynn M.

AU - Muss, Hyman B.

AU - Roberts, John D.

AU - Hurd, David D.

AU - Drabeek, Joseph J.

AU - Bartlett, Nancy

AU - Wadler, Scott

PY - 2005/7/20

Y1 - 2005/7/20

N2 - To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93% (95% confidence interval [CI] = 88% to 96%). Individual chemotherapy agents had similarly high sensitivities, ranging from 81% (95% CI = 70% to 89%) for carboplatin to 91% (95% CI = 79% to 98%) for cyclophosphamide. Agent-specific specificities were 100%. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.

AB - To determine the accuracy with which Medicare claims data measure chemotherapy use in elderly Medicare beneficiaries with cancer, we performed a criterion validation study. We compared gold-standard clinical trial data for 175 elderly cancer patients treated in two Cancer and Leukemia Group B (CALGB) breast and lung cancer trials (i.e., 45 from trial 9344 and 130 from trial 9730) with contemporaneous ambulatory and in-patient Medicare health insurance claims data from Centers for Medicare and Medicaid Services (CMS). The breast trial participants studied were those elderly enrolled between 1995 and 1997 and treated with doxorubicin and cyclophosphamide or this combination with paclitaxel. The lung trial participants studied were those elderly enrolled between 1998 and 2000 and treated with paclitaxel and carboplatin or paclitaxel alone. Comparing CALGB data with Medicare claims, we found the crude sensitivity for chemotherapy administration was 93% (95% confidence interval [CI] = 88% to 96%). Individual chemotherapy agents had similarly high sensitivities, ranging from 81% (95% CI = 70% to 89%) for carboplatin to 91% (95% CI = 79% to 98%) for cyclophosphamide. Agent-specific specificities were 100%. CMS data reliably captured repeat administration of chemotherapy to within one cycle. Administrative Medicare claims data appear to be a valid source of information for chemotherapy administered to elderly Medicare beneficiaries with cancer.

UR - http://www.scopus.com/inward/record.url?scp=23244459328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23244459328&partnerID=8YFLogxK

U2 - 10.1093/jnci/dji189

DO - 10.1093/jnci/dji189

M3 - Article

C2 - 16030306

AN - SCOPUS:23244459328

VL - 97

SP - 1080

EP - 1083

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 14

ER -